|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Global T-Cell Lymphoma Market was valued at USD 1,547.04 million in 2020, and it is expected to reach USD 2509.94 million by 2026, registering a CAGR of 8.25% during the period of 2021-2026.
Due to the high transmission rate of COVID_19 and lack of treatment, many countries suffered, and they are continuing to bear a significant burden on both their economies and healthcare systems. The COVID-19 outbreak may put patients with cutaneous lymphomas at additional risk of not receiving the necessary diagnostic procedures and treatment because they cannot access hospitals easily or due to healthcare resources limitations. Several guidelines for managing cutaneous lymphoma have been recently published to help dermatologists choose the right approach in the COVID-19 pandemic. However, these guidelines happen to be not applicable in countries that are still under a lockdown or do not have enough resources to implement the plan.
Moreover, the outbreak of COVID-19 impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and showed a huge impact on the general hospital care functioning for non-COVID-19 patients in hospitals across the world.
The growth of the T-Cell Lymphoma Market is attributed to the rise in lymphoma cancer incidence due to radiations, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.
According to Leukemia & Lymphoma Society 2020, an estimate of 85,720 new cases of lymphoma has been diagnosed in United States in the year 2020. In addition, the new reported lymphoma cases includes 8,480 cases of Hodgkin (HL), 77,240 cases Non-Hodgkin (NHL) Lymphoma. Moreover, there are around 644,761 people living with or in remission from non-Hodgkin lymphoma according to the same source in 2020. T-cell lymphoma is significantly contributing to non-Hodgkin lymphoma which further boosts the overall market growth.
In addition, the growing uptake of premium-priced products such as Keytruda, Opdivo and immune checkpoint inhibitors and the launch of several novel therapies with label extension of commercialized products are also boosting the overall market growth. However, high cost associated with T-cell lymphoma treatment and the adverse side effects of therapies have been obstructing the overall market growth.
Scope of the Report
As per scope of the report, Lymphoma occurs when a lymphocyte, a type of white blood cell, is out of control inside the body, affecting the body's immune capacity to fight against infection. Lymphomas are grouped as Hodgkin (abnormal B cells) and non-Hodgkin (developing from abnormal T cells or B cells) lymphomas. The Global T-Cell Lymphoma Market is Segmented by Type of Lymphoma (Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Other Types of Lymphoma), T-cell lymphoblastic lymphoma, Type of Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Other Type of Therapy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Type of Lymphoma|
|T-cell lymphoblastic lymphoma|
|By Type of Therapy|
|Stem Cell Transplantation|
|Other Type of Therapy|
Key Market Trends
Chemotherapy is Expected to Hold Significant Market Share over the Forecast Period
Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a particular area, but chemotherapy works throughout the whole body. This means that chemotherapy can destroy and damage cancer cells that have spread to other parts of the body away from the original tumor.
According to European Society for Medical Oncology, the COVID-pandemic had generated a huge backlog in oncology care and research. In addition, Cancer care was hit by the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment.
For instance, s per American Society of Clinical Oncology, Chemotherapy treatments and follow-ups were postponed during COVID-19 pandemic. Even private clinics in major Indian cities reported a nearly 50% decrease in patients for cancer care. Overall cancer services declined by 50% in April and May 2020.
Chemotherapy is used with surgery or radiation therapy, or both. In some cases, it is used in combination with other drugs, such as hormone therapy, targeted therapy, or immunotherapy. For example, chemo may be used to shrink a tumor before surgery or radiation therapy. Chemo used in this way is called neoadjuvant therapy or after surgery or radiation therapy to help kill any remaining cancer cells in the body. Chemo used in this way is called adjuvant therapy.
There are several types of chemotherapy being given to T-cell lymphoma patients, which include alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, and miscellaneous antineoplastics.
Favorable reimbursement policies with respect to these drugs making them accessible and affordable are expected to positively impact the market studied. For instance, Pralatrexate is a chemotherapy drug that is used in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) is listed under the PBS scheme by the Australian government.
Thus, with the rising awareness about the benefits of chemotherapy and favorable government policies, the market studied is expected to flourish during the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and it is Expected to do the Same over the Forecast Period
Some of the factors driving the market growth in North America region include high prevalence of T-cell lymphoma, presence of key market players and increasing research and development activities.
The outbreak of COVID-19 impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced in North America region. Some biopharmaceutical companies, such as Merck & Co. Inc. and Eli Lilly and Company, announced clinical trial delays. For instance, as per data from ClinicalTrials.gov showed that more than 200 interventional oncology studies were suspended in March and April 2020, as a result of the COVID-19 crisis. In addition, 60% of institutions in the United States are enrolling new patients at a lower rate.
According to the Globocan 2020 report, Canada had 8,506 cases of Non-Hodgkin lymphoma and 313 deaths caused due to it in 2020. This is expected to increase T-cell lymphoma incidence in the country. The increase in cases of Non-Hodgkin lymphoma is expected to boost the demand for treatment options, which is going to positively aid market development, as T-cell lymphomas are a type of Non-Hodgkin lymphoma.
Some of the major companies who operates in oncology segment in North America region are adopting several strategies such as collaboration and acquisition to strengthen its position in the T-cell lymphoma market. For instance, in August 2020 the company BostonGene Corporation announced the collaboration with The Weinstock Laboratory which is at Dana-Farber Cancer Institute, Inc.. The collaboration is focused on defining predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas. In addition, other companies, such as Amgen and Merck, have been working on developing cancer therapies for T-cell lymphomas. Hence the aforementioned factors are expected to fuel the market growth in this region.
To understand geography trends, Download Sample Report
The T-Cell Lymphoma Market is highly competitive and consists of a few major players. Companies, like Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc, F. Hoffmann-La Roche Ltd, hold the substantial share in the market.
In December 2020, the FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for the treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.
In July 2020, miRagen Therapeutics Inc. announced that the Food and Drug Administration (FDA) had granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is an inhibitor and is being developed by miRagen in two clinical programs to address different types of T-cell lymphomas, which include a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell lymphoma (ATLL).
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Lymphoma Cancer Incidence
4.2.2 Advancements in T-cell Lymphoma Specific Therapies
4.2.3 Risk of Lymphoma due to Autoimmune Disorders
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Adverse Side Effects of Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Lymphoma
5.1.1 Peripheral T-cell Lymphoma
220.127.116.11 Cutaneous T-cell Lymphoma
18.104.22.168 Anaplastic Large Cell Lymphoma
22.214.171.124 Angio-immuno-blastic T-cell Lymphoma
126.96.36.199 Other Types of Lymphoma
5.1.2 T-cell lymphoblastic lymphoma
5.2 By Type of Therapy
5.2.4 Stem Cell Transplantation
5.2.5 Other Type of Therapy
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Mundipharma International
6.1.2 Bristol-Myers Squibb Company
6.1.3 Genmab A/S
6.1.4 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
6.1.5 Merck & Co. Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Novartis AG
6.1.8 Autolus Therapeutics PLC
6.1.9 Acrotech Biopharma
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global T-Cell Lymphoma Market market is studied from 2018 - 2026.
What is the growth rate of Global T-Cell Lymphoma Market?
The Global T-Cell Lymphoma Market is growing at a CAGR of 8.25% over the next 5 years.
What is Global T-Cell Lymphoma Market size in 2018?
The Global T-Cell Lymphoma Market is valued at 1547 Million USD in 2018.
What is Global T-Cell Lymphoma Market size in 2026?
The Global T-Cell Lymphoma Market is valued at 2509 Million USD in 2026.
Which region has highest growth rate in Global T-Cell Lymphoma Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global T-Cell Lymphoma Market?
North America holds highest share in 2020.
Who are the key players in Global T-Cell Lymphoma Market?
Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc, F. Hoffmann-La Roche Ltd are the major companies operating in Global T-Cell Lymphoma Market.